| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Acute Lung Injury | 9 | 2022 | 30 | 2.590 |
Why?
|
| Respiratory Insufficiency | 7 | 2022 | 61 | 2.340 |
Why?
|
| Muscle, Skeletal | 11 | 2022 | 494 | 1.460 |
Why?
|
| Respiratory Distress Syndrome, Adult | 6 | 2017 | 55 | 1.340 |
Why?
|
| Critical Illness | 8 | 2020 | 87 | 1.340 |
Why?
|
| Muscular Atrophy | 6 | 2018 | 67 | 1.320 |
Why?
|
| Muscle Proteins | 4 | 2015 | 57 | 1.120 |
Why?
|
| Ubiquitin-Protein Ligases | 3 | 2015 | 32 | 1.030 |
Why?
|
| Sepsis | 3 | 2020 | 146 | 0.960 |
Why?
|
| Clodronic Acid | 1 | 2022 | 3 | 0.880 |
Why?
|
| Liposomes | 1 | 2022 | 26 | 0.870 |
Why?
|
| Coronavirus Infections | 5 | 2020 | 72 | 0.870 |
Why?
|
| Pneumonia, Viral | 5 | 2020 | 77 | 0.860 |
Why?
|
| Respiration, Artificial | 8 | 2021 | 96 | 0.850 |
Why?
|
| Humans | 47 | 2022 | 28998 | 0.800 |
Why?
|
| Ascorbic Acid | 1 | 2020 | 21 | 0.760 |
Why?
|
| Exercise Therapy | 3 | 2020 | 229 | 0.750 |
Why?
|
| Survivors | 3 | 2021 | 144 | 0.730 |
Why?
|
| Beta vulgaris | 1 | 2019 | 11 | 0.720 |
Why?
|
| Nitrates | 1 | 2019 | 25 | 0.720 |
Why?
|
| Hand Strength | 3 | 2019 | 85 | 0.700 |
Why?
|
| Fellowships and Scholarships | 1 | 2019 | 50 | 0.700 |
Why?
|
| Male | 37 | 2022 | 17767 | 0.670 |
Why?
|
| Wasting Syndrome | 2 | 2015 | 14 | 0.650 |
Why?
|
| Biomedical Research | 1 | 2019 | 153 | 0.640 |
Why?
|
| Research Design | 1 | 2019 | 285 | 0.630 |
Why?
|
| Mice, Inbred C57BL | 12 | 2022 | 711 | 0.620 |
Why?
|
| Frail Elderly | 1 | 2018 | 65 | 0.620 |
Why?
|
| Disabled Persons | 1 | 2018 | 83 | 0.610 |
Why?
|
| Walking | 1 | 2018 | 177 | 0.590 |
Why?
|
| Endocarditis | 1 | 2016 | 11 | 0.580 |
Why?
|
| Muscle Weakness | 2 | 2019 | 39 | 0.570 |
Why?
|
| Injections | 1 | 2016 | 61 | 0.570 |
Why?
|
| Length of Stay | 5 | 2020 | 291 | 0.570 |
Why?
|
| Muscle Strength | 5 | 2019 | 139 | 0.570 |
Why?
|
| Physical Conditioning, Animal | 2 | 2017 | 32 | 0.560 |
Why?
|
| Intensive Care Units | 7 | 2019 | 118 | 0.550 |
Why?
|
| Female | 31 | 2021 | 18112 | 0.550 |
Why?
|
| Mice | 16 | 2022 | 2368 | 0.550 |
Why?
|
| Antiviral Agents | 3 | 2021 | 100 | 0.530 |
Why?
|
| Aged | 22 | 2021 | 9461 | 0.530 |
Why?
|
| Animals | 21 | 2022 | 7296 | 0.530 |
Why?
|
| Critical Care | 7 | 2019 | 114 | 0.520 |
Why?
|
| Neutrophils | 2 | 2015 | 102 | 0.520 |
Why?
|
| Disease Progression | 2 | 2021 | 572 | 0.500 |
Why?
|
| Adult | 23 | 2022 | 8391 | 0.480 |
Why?
|
| Laryngeal Muscles | 1 | 2014 | 16 | 0.480 |
Why?
|
| Analgesics, Opioid | 1 | 2016 | 236 | 0.470 |
Why?
|
| Hospitalization | 5 | 2022 | 417 | 0.460 |
Why?
|
| Middle Aged | 23 | 2021 | 10805 | 0.450 |
Why?
|
| Lipopolysaccharides | 8 | 2021 | 107 | 0.430 |
Why?
|
| Antibodies, Neutralizing | 2 | 2021 | 17 | 0.410 |
Why?
|
| Quality of Life | 4 | 2022 | 814 | 0.400 |
Why?
|
| Personnel, Hospital | 2 | 2020 | 12 | 0.390 |
Why?
|
| Prospective Studies | 8 | 2022 | 2010 | 0.380 |
Why?
|
| Antibodies, Viral | 2 | 2020 | 55 | 0.380 |
Why?
|
| Macrophages | 2 | 2022 | 188 | 0.370 |
Why?
|
| Tidal Volume | 1 | 2019 | 13 | 0.350 |
Why?
|
| Clinical Trials as Topic | 2 | 2022 | 298 | 0.340 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2013 | 871 | 0.320 |
Why?
|
| Blood Gas Analysis | 1 | 2017 | 16 | 0.310 |
Why?
|
| Calpain | 2 | 2017 | 12 | 0.290 |
Why?
|
| Acute Disease | 3 | 2019 | 239 | 0.290 |
Why?
|
| Double-Blind Method | 4 | 2021 | 501 | 0.290 |
Why?
|
| Ultrasonography | 2 | 2019 | 345 | 0.280 |
Why?
|
| Asthma | 1 | 2009 | 397 | 0.280 |
Why?
|
| Troponin T | 2 | 2017 | 57 | 0.280 |
Why?
|
| Patient Discharge | 4 | 2019 | 168 | 0.270 |
Why?
|
| Mice, Knockout | 7 | 2016 | 425 | 0.270 |
Why?
|
| Aging | 3 | 2017 | 880 | 0.270 |
Why?
|
| T-Lymphocytes, Regulatory | 3 | 2016 | 33 | 0.260 |
Why?
|
| Adenosine Monophosphate | 2 | 2021 | 6 | 0.260 |
Why?
|
| United States | 9 | 2022 | 3604 | 0.260 |
Why?
|
| European Continental Ancestry Group | 1 | 2009 | 1131 | 0.260 |
Why?
|
| Alanine | 2 | 2021 | 27 | 0.260 |
Why?
|
| Macrophages, Alveolar | 2 | 2016 | 9 | 0.260 |
Why?
|
| Vaccination | 2 | 2022 | 123 | 0.250 |
Why?
|
| Oxygen | 3 | 2022 | 139 | 0.240 |
Why?
|
| Emergency Service, Hospital | 1 | 2017 | 429 | 0.240 |
Why?
|
| Inpatients | 2 | 2022 | 64 | 0.230 |
Why?
|
| Treatment Outcome | 4 | 2022 | 3094 | 0.220 |
Why?
|
| Receptors, CCR5 | 1 | 2022 | 3 | 0.220 |
Why?
|
| Sulfoxides | 1 | 2022 | 2 | 0.220 |
Why?
|
| Receptors, CCR2 | 1 | 2022 | 2 | 0.220 |
Why?
|
| Muscle Fibers, Fast-Twitch | 3 | 2017 | 29 | 0.220 |
Why?
|
| African Americans | 1 | 2009 | 1373 | 0.210 |
Why?
|
| Bayes Theorem | 1 | 2022 | 66 | 0.210 |
Why?
|
| Imidazoles | 1 | 2022 | 104 | 0.210 |
Why?
|
| Organ Transplantation | 1 | 2022 | 65 | 0.210 |
Why?
|
| Immunocompromised Host | 1 | 2021 | 43 | 0.200 |
Why?
|
| Young Adult | 5 | 2021 | 2398 | 0.200 |
Why?
|
| Telecommunications | 1 | 2020 | 5 | 0.200 |
Why?
|
| Work | 1 | 2020 | 7 | 0.200 |
Why?
|
| Contact Tracing | 1 | 2020 | 8 | 0.190 |
Why?
|
| Thiamine | 1 | 2020 | 4 | 0.190 |
Why?
|
| Pilot Projects | 2 | 2019 | 469 | 0.190 |
Why?
|
| Community-Acquired Infections | 1 | 2020 | 31 | 0.190 |
Why?
|
| Outpatients | 1 | 2020 | 49 | 0.190 |
Why?
|
| Hydrocortisone | 1 | 2020 | 61 | 0.190 |
Why?
|
| Sulfonamides | 2 | 2017 | 65 | 0.180 |
Why?
|
| Vitamins | 1 | 2020 | 58 | 0.180 |
Why?
|
| Tumor Necrosis Factor-alpha | 1 | 2021 | 200 | 0.180 |
Why?
|
| Financing, Organized | 1 | 2019 | 14 | 0.180 |
Why?
|
| Nitrites | 1 | 2019 | 20 | 0.180 |
Why?
|
| Physical Therapy Modalities | 2 | 2019 | 60 | 0.180 |
Why?
|
| Environmental Exposure | 1 | 2020 | 86 | 0.180 |
Why?
|
| Obesity | 2 | 2018 | 1062 | 0.180 |
Why?
|
| Atracurium | 1 | 2019 | 1 | 0.180 |
Why?
|
| Neuromuscular Blocking Agents | 1 | 2019 | 6 | 0.180 |
Why?
|
| Positive-Pressure Respiration | 1 | 2019 | 7 | 0.180 |
Why?
|
| Severity of Illness Index | 4 | 2022 | 863 | 0.180 |
Why?
|
| Cough | 1 | 2019 | 19 | 0.180 |
Why?
|
| Dyspnea | 1 | 2019 | 30 | 0.180 |
Why?
|
| Muscle Fibers, Skeletal | 2 | 2021 | 104 | 0.180 |
Why?
|
| Amino Acids | 1 | 2019 | 41 | 0.170 |
Why?
|
| Teaching | 1 | 2019 | 55 | 0.170 |
Why?
|
| Fear | 1 | 2019 | 44 | 0.170 |
Why?
|
| Retrospective Studies | 4 | 2019 | 3100 | 0.170 |
Why?
|
| Nutritional Status | 1 | 2019 | 68 | 0.170 |
Why?
|
| Receptors, Cholinergic | 1 | 2018 | 21 | 0.170 |
Why?
|
| Sympathetic Nervous System | 1 | 2018 | 29 | 0.170 |
Why?
|
| Acetylcholine | 1 | 2018 | 47 | 0.170 |
Why?
|
| Case-Control Studies | 4 | 2022 | 855 | 0.170 |
Why?
|
| Quadriceps Muscle | 1 | 2018 | 31 | 0.170 |
Why?
|
| Enteral Nutrition | 1 | 2018 | 30 | 0.170 |
Why?
|
| Dietary Supplements | 1 | 2019 | 170 | 0.160 |
Why?
|
| Recovery of Function | 1 | 2019 | 190 | 0.160 |
Why?
|
| Chemokines | 2 | 2015 | 35 | 0.160 |
Why?
|
| Ganciclovir | 1 | 2017 | 14 | 0.160 |
Why?
|
| Pulmonary Disease, Chronic Obstructive | 1 | 2019 | 120 | 0.160 |
Why?
|
| Protein Phosphatase 1 | 1 | 2017 | 5 | 0.160 |
Why?
|
| Cytomegalovirus | 1 | 2017 | 20 | 0.160 |
Why?
|
| Pulmonary Alveoli | 2 | 2015 | 19 | 0.160 |
Why?
|
| Bronchoalveolar Lavage Fluid | 3 | 2013 | 67 | 0.160 |
Why?
|
| Cytomegalovirus Infections | 1 | 2017 | 25 | 0.150 |
Why?
|
| Accidental Falls | 1 | 2019 | 204 | 0.150 |
Why?
|
| Lipolysis | 1 | 2017 | 17 | 0.150 |
Why?
|
| Angioedema | 1 | 2017 | 3 | 0.150 |
Why?
|
| Muscle Denervation | 1 | 2017 | 28 | 0.150 |
Why?
|
| Drug Users | 1 | 2016 | 7 | 0.150 |
Why?
|
| Interleukin-6 | 1 | 2017 | 224 | 0.140 |
Why?
|
| Overweight | 1 | 2018 | 256 | 0.140 |
Why?
|
| Southeastern United States | 1 | 2016 | 71 | 0.140 |
Why?
|
| Interleukin-4 | 1 | 2016 | 20 | 0.140 |
Why?
|
| Treatment Failure | 3 | 2021 | 159 | 0.140 |
Why?
|
| Inflammation | 2 | 2021 | 503 | 0.140 |
Why?
|
| Patient Advocacy | 1 | 2015 | 13 | 0.140 |
Why?
|
| Down-Regulation | 2 | 2017 | 142 | 0.140 |
Why?
|
| Blood Glucose | 1 | 2018 | 465 | 0.140 |
Why?
|
| Smoking | 1 | 2019 | 427 | 0.140 |
Why?
|
| Calcium Channels, L-Type | 1 | 2016 | 45 | 0.140 |
Why?
|
| Receptors, Granulocyte Colony-Stimulating Factor | 1 | 2015 | 8 | 0.130 |
Why?
|
| Granulocyte Colony-Stimulating Factor | 1 | 2015 | 21 | 0.130 |
Why?
|
| Random Allocation | 2 | 2014 | 212 | 0.130 |
Why?
|
| Wounds and Injuries | 1 | 2017 | 249 | 0.130 |
Why?
|
| Cell Proliferation | 2 | 2014 | 573 | 0.130 |
Why?
|
| Pericytes | 1 | 2014 | 28 | 0.130 |
Why?
|
| Physical Endurance | 1 | 2014 | 31 | 0.130 |
Why?
|
| Respiratory Mucosa | 1 | 2014 | 10 | 0.130 |
Why?
|
| Cicatrix | 1 | 2014 | 36 | 0.130 |
Why?
|
| HSP70 Heat-Shock Proteins | 1 | 2014 | 25 | 0.120 |
Why?
|
| Weight Loss | 1 | 2017 | 413 | 0.120 |
Why?
|
| Lipids | 1 | 2015 | 208 | 0.120 |
Why?
|
| Vocal Cords | 1 | 2014 | 8 | 0.120 |
Why?
|
| Disease Models, Animal | 3 | 2012 | 980 | 0.120 |
Why?
|
| Time Factors | 2 | 2019 | 1997 | 0.120 |
Why?
|
| Randomized Controlled Trials as Topic | 3 | 2022 | 462 | 0.120 |
Why?
|
| Hospital Mortality | 2 | 2019 | 186 | 0.120 |
Why?
|
| Gene Expression Regulation | 2 | 2017 | 481 | 0.120 |
Why?
|
| Receptor, Adenosine A2A | 1 | 2013 | 5 | 0.120 |
Why?
|
| Immediate-Early Proteins | 1 | 2012 | 9 | 0.110 |
Why?
|
| Nitric Oxide Synthase Type II | 1 | 2012 | 12 | 0.110 |
Why?
|
| Protein-Serine-Threonine Kinases | 1 | 2012 | 44 | 0.110 |
Why?
|
| Motor Activity | 1 | 2015 | 310 | 0.110 |
Why?
|
| Vaccines, Synthetic | 2 | 2022 | 11 | 0.110 |
Why?
|
| RING Finger Domains | 1 | 2012 | 2 | 0.110 |
Why?
|
| Hypertension, Pulmonary | 1 | 2011 | 23 | 0.100 |
Why?
|
| Aged, 80 and over | 5 | 2019 | 3712 | 0.100 |
Why?
|
| Apoptosis Regulatory Proteins | 1 | 2011 | 33 | 0.100 |
Why?
|
| Sarcolemma | 1 | 2011 | 3 | 0.100 |
Why?
|
| Insulin Resistance | 1 | 2014 | 449 | 0.100 |
Why?
|
| Nitric Oxide Synthase Type I | 1 | 2011 | 17 | 0.100 |
Why?
|
| Blotting, Western | 1 | 2012 | 281 | 0.100 |
Why?
|
| Monocytes | 1 | 2012 | 119 | 0.100 |
Why?
|
| Neuromuscular Diseases | 1 | 2011 | 13 | 0.100 |
Why?
|
| Adolescent | 4 | 2021 | 3248 | 0.100 |
Why?
|
| Drug Therapy, Combination | 2 | 2021 | 273 | 0.090 |
Why?
|
| Sensitivity and Specificity | 1 | 2012 | 531 | 0.090 |
Why?
|
| Ambulatory Care Facilities | 2 | 2020 | 63 | 0.090 |
Why?
|
| Immunohistochemistry | 1 | 2012 | 519 | 0.090 |
Why?
|
| Multivariate Analysis | 1 | 2012 | 636 | 0.090 |
Why?
|
| Cross-Sectional Studies | 3 | 2022 | 1353 | 0.090 |
Why?
|
| Intention to Treat Analysis | 2 | 2020 | 23 | 0.090 |
Why?
|
| Lung Injury | 1 | 2009 | 64 | 0.090 |
Why?
|
| Academic Medical Centers | 2 | 2020 | 150 | 0.090 |
Why?
|
| Follow-Up Studies | 2 | 2019 | 2105 | 0.080 |
Why?
|
| Feasibility Studies | 1 | 2019 | 262 | 0.080 |
Why?
|
| Healthcare Disparities | 1 | 2009 | 153 | 0.080 |
Why?
|
| Oximetry | 1 | 2017 | 28 | 0.080 |
Why?
|
| Neuromuscular Junction | 2 | 2018 | 67 | 0.080 |
Why?
|
| Health Status | 2 | 2022 | 368 | 0.070 |
Why?
|
| Inflammation Mediators | 3 | 2013 | 101 | 0.070 |
Why?
|
| Data Interpretation, Statistical | 1 | 2017 | 103 | 0.070 |
Why?
|
| Synaptic Transmission | 2 | 2018 | 113 | 0.070 |
Why?
|
| Child | 2 | 2011 | 2209 | 0.070 |
Why?
|
| Survival Rate | 1 | 2019 | 795 | 0.070 |
Why?
|
| Muscle Fibers, Slow-Twitch | 2 | 2016 | 20 | 0.070 |
Why?
|
| Muscle Contraction | 2 | 2017 | 114 | 0.070 |
Why?
|
| Incidence | 1 | 2019 | 1105 | 0.070 |
Why?
|
| Cytokines | 2 | 2021 | 243 | 0.070 |
Why?
|
| Chi-Square Distribution | 2 | 2019 | 292 | 0.060 |
Why?
|
| Fluorescent Antibody Technique | 2 | 2017 | 82 | 0.060 |
Why?
|
| Forkhead Transcription Factors | 2 | 2014 | 26 | 0.060 |
Why?
|
| Cell Line | 2 | 2016 | 449 | 0.060 |
Why?
|
| Body Composition | 2 | 2015 | 365 | 0.060 |
Why?
|
| Nucleocapsid | 1 | 2022 | 6 | 0.060 |
Why?
|
| Sciuridae | 2 | 2012 | 2 | 0.050 |
Why?
|
| Immunization Schedule | 1 | 2022 | 24 | 0.050 |
Why?
|
| Risk Factors | 2 | 2020 | 3509 | 0.050 |
Why?
|
| Medical Futility | 1 | 2021 | 2 | 0.050 |
Why?
|
| Antigens, Viral | 1 | 2021 | 18 | 0.050 |
Why?
|
| RNA, Viral | 1 | 2021 | 49 | 0.050 |
Why?
|
| Infectious Disease Transmission, Professional-to-Patient | 1 | 2020 | 4 | 0.050 |
Why?
|
| Seroepidemiologic Studies | 1 | 2020 | 9 | 0.050 |
Why?
|
| RNA, Messenger | 1 | 2022 | 514 | 0.050 |
Why?
|
| Cross Infection | 1 | 2020 | 46 | 0.050 |
Why?
|
| Cells, Cultured | 2 | 2013 | 799 | 0.050 |
Why?
|
| Ergometry | 1 | 2019 | 4 | 0.050 |
Why?
|
| Gene Expression | 1 | 2021 | 332 | 0.040 |
Why?
|
| Neuromuscular Blockade | 1 | 2019 | 6 | 0.040 |
Why?
|
| Glucocorticoids | 1 | 2020 | 149 | 0.040 |
Why?
|
| Conscious Sedation | 1 | 2019 | 24 | 0.040 |
Why?
|
| Multicenter Studies as Topic | 1 | 2019 | 92 | 0.040 |
Why?
|
| Subacute Care | 1 | 2019 | 11 | 0.040 |
Why?
|
| APACHE | 1 | 2019 | 12 | 0.040 |
Why?
|
| Socioeconomic Factors | 1 | 2020 | 385 | 0.040 |
Why?
|
| Signal Transduction | 2 | 2012 | 666 | 0.040 |
Why?
|
| Food, Formulated | 1 | 2018 | 10 | 0.040 |
Why?
|
| Dietary Carbohydrates | 1 | 2018 | 21 | 0.040 |
Why?
|
| Shock, Septic | 1 | 2018 | 28 | 0.040 |
Why?
|
| Dietary Proteins | 1 | 2018 | 50 | 0.040 |
Why?
|
| Motor Neurons | 1 | 2018 | 53 | 0.040 |
Why?
|
| Activities of Daily Living | 1 | 2019 | 237 | 0.040 |
Why?
|
| Hyperglycemia | 1 | 2018 | 82 | 0.040 |
Why?
|
| Energy Intake | 1 | 2018 | 120 | 0.040 |
Why?
|
| Virus Activation | 1 | 2017 | 7 | 0.040 |
Why?
|
| Combined Modality Therapy | 1 | 2019 | 523 | 0.040 |
Why?
|
| Comorbidity | 1 | 2019 | 539 | 0.040 |
Why?
|
| Pharmacogenetics | 1 | 2017 | 35 | 0.040 |
Why?
|
| Cyclic AMP-Dependent Protein Kinase RIIalpha Subunit | 1 | 2017 | 8 | 0.040 |
Why?
|
| Complement C1 Inactivator Proteins | 1 | 2017 | 1 | 0.040 |
Why?
|
| Kallikreins | 1 | 2017 | 2 | 0.040 |
Why?
|
| Complement C1 Inhibitor Protein | 1 | 2017 | 2 | 0.040 |
Why?
|
| Bradykinin | 1 | 2017 | 18 | 0.040 |
Why?
|
| Longitudinal Studies | 1 | 2019 | 708 | 0.040 |
Why?
|
| Sex Factors | 1 | 2019 | 626 | 0.040 |
Why?
|
| Logistic Models | 1 | 2019 | 725 | 0.040 |
Why?
|
| Reproducibility of Results | 1 | 2019 | 724 | 0.040 |
Why?
|
| Peptides | 1 | 2017 | 118 | 0.040 |
Why?
|
| Recombinant Proteins | 1 | 2017 | 248 | 0.040 |
Why?
|
| Insulin | 1 | 2018 | 346 | 0.040 |
Why?
|
| Action Potentials | 1 | 2017 | 174 | 0.040 |
Why?
|
| Macrophage Activation | 1 | 2016 | 9 | 0.040 |
Why?
|
| Isometric Contraction | 1 | 2016 | 21 | 0.040 |
Why?
|
| Muscle Fatigue | 1 | 2016 | 11 | 0.040 |
Why?
|
| Electrophoretic Mobility Shift Assay | 1 | 2016 | 17 | 0.040 |
Why?
|
| Protein Stability | 1 | 2016 | 26 | 0.040 |
Why?
|
| Third-Party Consent | 1 | 2015 | 2 | 0.030 |
Why?
|
| Resuscitation Orders | 1 | 2015 | 11 | 0.030 |
Why?
|
| Uncertainty | 1 | 2015 | 12 | 0.030 |
Why?
|
| Gene Knockdown Techniques | 1 | 2016 | 73 | 0.030 |
Why?
|
| Drug Evaluation, Preclinical | 1 | 2016 | 58 | 0.030 |
Why?
|
| Terminal Care | 1 | 2015 | 18 | 0.030 |
Why?
|
| Torque | 1 | 2015 | 19 | 0.030 |
Why?
|
| Mice, Inbred BALB C | 1 | 2016 | 160 | 0.030 |
Why?
|
| Resistance Training | 1 | 2016 | 70 | 0.030 |
Why?
|
| Protein Binding | 1 | 2016 | 199 | 0.030 |
Why?
|
| Emotions | 1 | 2015 | 46 | 0.030 |
Why?
|
| Mental Health | 1 | 2016 | 102 | 0.030 |
Why?
|
| Transcription, Genetic | 1 | 2016 | 136 | 0.030 |
Why?
|
| Promoter Regions, Genetic | 1 | 2016 | 212 | 0.030 |
Why?
|
| Cell Nucleus | 1 | 2016 | 105 | 0.030 |
Why?
|
| Family | 1 | 2015 | 105 | 0.030 |
Why?
|
| Organ Specificity | 1 | 2014 | 77 | 0.030 |
Why?
|
| Diterpenes | 1 | 2014 | 15 | 0.030 |
Why?
|
| Integrin alpha Chains | 1 | 2014 | 3 | 0.030 |
Why?
|
| Antigens, CD | 1 | 2014 | 100 | 0.030 |
Why?
|
| Age Factors | 1 | 2017 | 1105 | 0.030 |
Why?
|
| Phenethylamines | 1 | 2013 | 2 | 0.030 |
Why?
|
| Oxygen Inhalation Therapy | 1 | 2013 | 8 | 0.030 |
Why?
|
| Gene Knockout Techniques | 1 | 2013 | 11 | 0.030 |
Why?
|
| Collagen | 1 | 2014 | 216 | 0.030 |
Why?
|
| Adenosine | 1 | 2013 | 41 | 0.030 |
Why?
|
| Starvation | 1 | 2012 | 2 | 0.030 |
Why?
|
| Hibernation | 1 | 2012 | 2 | 0.030 |
Why?
|
| Heterocyclic Compounds | 1 | 2012 | 8 | 0.030 |
Why?
|
| Receptors, CXCR4 | 1 | 2012 | 11 | 0.030 |
Why?
|
| DNA Primers | 1 | 2012 | 87 | 0.030 |
Why?
|
| Adoptive Transfer | 1 | 2012 | 16 | 0.030 |
Why?
|
| Mice, Congenic | 1 | 2012 | 2 | 0.030 |
Why?
|
| Chemokine CXCL12 | 1 | 2012 | 25 | 0.030 |
Why?
|
| Cell Line, Transformed | 1 | 2012 | 13 | 0.030 |
Why?
|
| Enzyme Activation | 1 | 2012 | 126 | 0.030 |
Why?
|
| Macrophages, Peritoneal | 1 | 2012 | 19 | 0.030 |
Why?
|
| Proto-Oncogene Proteins c-akt | 1 | 2012 | 69 | 0.030 |
Why?
|
| Homeodomain Proteins | 1 | 2012 | 50 | 0.030 |
Why?
|
| Base Sequence | 1 | 2012 | 240 | 0.030 |
Why?
|
| Homeostasis | 1 | 2012 | 127 | 0.030 |
Why?
|
| Pulmonary Circulation | 1 | 2011 | 4 | 0.030 |
Why?
|
| Fibroblasts | 1 | 2012 | 103 | 0.030 |
Why?
|
| Mice, Transgenic | 1 | 2012 | 249 | 0.030 |
Why?
|
| Potassium Channels, Voltage-Gated | 1 | 2011 | 13 | 0.030 |
Why?
|
| Cell Death | 1 | 2011 | 71 | 0.030 |
Why?
|
| Cell Division | 1 | 2011 | 97 | 0.030 |
Why?
|
| Vasoconstriction | 1 | 2011 | 40 | 0.030 |
Why?
|
| Hyperthermia, Induced | 1 | 2014 | 235 | 0.030 |
Why?
|
| Muscular Dystrophy, Animal | 1 | 2011 | 1 | 0.030 |
Why?
|
| Muscle, Smooth, Vascular | 1 | 2011 | 71 | 0.030 |
Why?
|
| Lung | 1 | 2013 | 233 | 0.030 |
Why?
|
| Up-Regulation | 1 | 2011 | 183 | 0.020 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2011 | 248 | 0.020 |
Why?
|
| Leukocyte Reduction Procedures | 1 | 2009 | 2 | 0.020 |
Why?
|
| Cell Membrane Permeability | 1 | 2009 | 14 | 0.020 |
Why?
|
| Chronic Disease | 1 | 2011 | 369 | 0.020 |
Why?
|
| Leukocyte Count | 1 | 2009 | 55 | 0.020 |
Why?
|
| Epithelial Cells | 1 | 2009 | 138 | 0.020 |
Why?
|
| Endothelial Cells | 1 | 2009 | 179 | 0.020 |
Why?
|
| Infant | 1 | 2011 | 967 | 0.020 |
Why?
|
| Rats | 1 | 2011 | 1604 | 0.020 |
Why?
|
| Child, Preschool | 1 | 2011 | 1164 | 0.020 |
Why?
|